References
- Control of communicable diseases in man, 17th ed. American Public HealthAssociation, 2000
- Control of epidemic meningococcal disease. WHO practical guidelines, 2."' ed. WHO/EMC/BAC/98.3 (downloaded from WHO website), January 1997. WHO Working Group
- Musher DM. How infectious are common respiratory tract infections? N Engl J Med 2003; 348: 1256–1266
- Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as risk factor for meningococcal disease. Paediatr Infect Dis J1997; 16:979–983
- South African Medicines Formulary, 7th ed. Cape Town: South African MedicalAssociation, 2005
- Burke P, Burne SR. Allergy associated with ciprofloxacin. BMJ 2000; 320:679
- Wanke LA, Bryson JL. Quinolone use in paediatrics. Drugdex. Micromedex® Health Care Series, Vol 118
- Communicable Diseases Communique. National Institute for Communicable Diseases, National Health Laboratory Service, South Africa, September, 2003
- Jodar L, LaForce FM, Ceccarini C, Aguada T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of vaccines for the poorest countries. Lancet 2003 ; 361: 1902–1904
- Jodar L, Feavers /M, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359: 1499–1508
- Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195–196
- Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ2003; 326:365–366
- Meningococcal disease and follow up of contacts. Regional Circular No. 26/2000, Metropole Region, Provincial Administration: Western Cape, 25 August 2000
- Epidemiological Comments. Dept of Health, Republic of SouthAfrica. Vol 2, No 2, April- June 2000
- Epidemiological Comments. Dept of Health, Republic of SouthAfrica. Vol 24, No 4, April 1998
- Communicable Diseases Communique. National Institute for Communicable Diseases, National Health Laboratory Service, South Africa, September, 2003
- Judy Caldwell, Department of Health, Cape Metropole Region, personal communication.
- Dave Dunheim, personal communication
- Public Health Forum, Health Science Faculty, Stellenbosch University, 22'd October 2003
- Leake JAD. Meningococcal Disease: Challenges in Prevention and Management. Infect Med2000; 17:364–377
- Meningococcal Disease and College Students. MMWR 2002; 49 (RR07): 11–20
- Watson R, Biovac SA
- Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191–2196
- Vermont CL, Van Dijken HH, Kuipers AJ, et al. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun 2003; 71: 1650–1655
- Martin SL, Borrow R, Van der Ley P, Dawson M, Fox AJ, Cartright KAV. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000; 18:24762481